Loading…
← CockpitCompetitor Analysis › ORCHPHARMA.NS Orchid Pharma LimitedOpen in the cockpit ↗

Orchid Pharma LimitedORCHPHARMA.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Momentum strong 77
Mkt cap
$613M
US dollars, full cap
Free float
30%
of shares outstanding
$/day
$1.07M
20-day average traded
Fwd P/E
83.1×
forward earnings
ROIC−WACC
-19.0 pp
WACC 19.1%
Hurdle
n/a
no reverse DCF
Next earnings
85 days
11 Feb 2027
Close · INR₹955.95
1D+2.7%
1W+10.3%
1M+7.0%
3M-1.4%
6M+29.9%
YTD+26.0%
1Y+17.9%
ATR %4.9%
Beta0.98
52w lowhigh16.4% off high

What Orchid Pharma does

Employees: 1,461

Orchid Pharma at a glance

Size Orchid Pharma (ORCHPHARMA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $613M, the 776th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹955.95 on 18 Nov 2026.

Performance Over six months the shares gained 29.9%, against -26.6% for the median peer and +3.8% for the India market (cap-weighted) — highest of 20 in its peer set.

Growth Revenue grew 10.8% over the last twelve months (peer median +4.6%); the operating margin is 0.3% (peer median 4.4%).

Valuation It trades at 83.1× forward earnings against a peer median of 10.8× (most expensive of 7).

Capital Return on invested capital runs 19.0 points below its cost of capital (19.1% WACC).

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026ORCHPHARMA.NS 134Peer median 75
Six months, rebased to 100: Orchid Pharma against the median of its 20 peers (local-currency closes).

Orchid Pharma financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹9.43B₹12.3B₹13.9B₹8.19B₹6.66B
Revenue growth—-12%+70%+23%—
Gross profit₹1.76B₹867M₹1.98B₹1.36B₹707M
EBITDA₹410M₹462M₹1.48B₹1.11B₹845M
Net income₹86.7M₹99.6M₹1.35B₹922M₹463M
Free cash flown/a-₹2.62B-₹940M₹568M-₹983M
Capital expendituren/a₹3.90B₹1.54B₹648M₹849M
Total debtn/a₹3.07B₹1.54B₹2.04B₹4.00B

Quarterly statements and history in the cockpit →

Orchid Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-50%0%+50%4105300194002940603567002793185750OLMA301211BCAXDBV300233600976IMMX300878300147ORCHPHARMA.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Orchid Pharma is the large dot.

Fundamentals: revenue growth against valuation

-75%-50%-25%0%+25%0×25×50×75×4105603567185750301096600976300016ORCHPHARMA.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Orchid Pharma is the large dot.

Orchid Pharma competitors and peer comparison

How Orchid Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Orchid Pharma against its 20 peers (data as of 18 Nov 2026)
MeasureORCHPHARMA.NSPeer medianRank in peer set
1-month return+7.0%-10.7%2nd highest of 20
6-month return+29.9%-26.6%highest of 20
Distance from 52-week high-16.4%-41.0%2nd highest of 20
Revenue growth (TTM)+10.8%+4.6%6th highest of 16
Operating margin0.3%4.4%6th lowest of 15
Forward P/E83.1×10.8×most expensive of 7
ROIC minus cost of capital-19.0 pp-3.9 pp2nd lowest of 14
Net debt / EBITDA5.5×0.1×most indebted of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Orchid Pharma ORCHPHARMA.NSIndia$613M+30%+11%0%83.1×n/an/a
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%10.2×-8.7%+8.8%
Fuan Pharmaceutical (Group) 300194.SZChina$612M-14%-3%-1%n/a10.9%-5.9%
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%n/a10.1%+2.1%
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a5.4×9.1%-25.1%
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a
Luoxin Pharmaceuticals Group Stock 002793.SZChina$609M-26%-10%-9%n/a-1.0%-17.9%
Chongkundang 185750.KSSouth Korea$609M-27%+6%4%11.4×-6.6%+5.4%
Olema Pharmaceuticals OLMAUnited States$619M-49%n/an/an/an/an/a
Hubei Biocause Heilen Pharmaceutical 301211.SZChina$619M-10%+13%4%n/an/an/a
Bicara Therapeutics BCAXUnited States$623M-54%n/an/an/an/an/a
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%n/a-0.6%-1.6%
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%54.0×n/an/a
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%6.7×-6.2%+6.5%
Arbutus Biopharma ABUSUnited States$630M-6%+1,143%80%n/an/an/a
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a
Zhejiang Wecome Pharmaceutical 300878.SZChina$632M-18%+92%-41%n/an/an/a
Xiangxue Pharmaceutical 300147.SZChina$591M-41%+3%-39%n/a50.4%-12.3%
Center Laboratories 4123.TWOTaiwan$639M-29%+14%9%n/a36.3%+16.2%
Beijing Beilu Pharmaceutical 300016.SZChina$641M-19%+23%11%79.7×9.1%+7.9%

Questions

Which companies are Orchid Pharma's closest peers?
The cockpit's peer set: TTY Biopharm (4105.TWO), Fuan Pharmaceutical (Group) (300194.SZ), Zhejiang Anglikang Pharmaceutical (002940.SZ), HeiLongJiang ZBD Pharmaceutical (603567.SS), Achieve Life Sciences (QUIT), Luoxin Pharmaceuticals Group Stock (002793.SZ), Chongkundang (185750.KS), Olema Pharmaceuticals (OLMA).
Is Orchid Pharma expensive compared with its peers?
On forward p/e it trades at 83.1× against a peer median of 10.8×, most expensive of 7 in its peer set.
How has Orchid Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned +29.9% against -26.6% for the median peer; over one year +17.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.